Study Description
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.
Interventions
PDR001
Eligibility Criteria
Inclusion Criteria:
Subject is currently enrolled in a pre-defined Novartis-sponsored study and is receiving spartalizumab as single agent or in combination with other study treatment,
Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.
Other protocol defined inclusion criteria may apply
Exclusion Criteria:
Subject has been permanently discontinued from spartalizumab in the parent protocol for any reason other than enrollment in the Roll over Study
Subject does not meet the criteria specified in the parent protocol criteria for continued study treatment.
Study Location
Novartis Investigative Site
Recruiting
Leuven,3000,Belgium
Novartis Investigative Site
Recruiting
Liege,4000,Belgium
Novartis Investigative Site
Recruiting
Montreal,Quebec,H3T 1E2,Canada
Novartis Investigative Site
Recruiting
Toronto,Ontario,M5G 2M9,Canada
Novartis Investigative Site
Recruiting
Guangzhou,510060,China
Novartis Investigative Site
Recruiting
Brno,Czech Republic,656 53,Czech Republic
Novartis Investigative Site
Recruiting
Heidelberg,69120,Germany
Novartis Investigative Site
Recruiting
Ulm,89081,Germany
Novartis Investigative Site
Recruiting
Jena,07740,Germany
Novartis Investigative Site
Recruiting
Essen,45147,Germany
Novartis Investigative Site
Recruiting
Shatin New Territories,Hong Kong
Novartis Investigative Site
Recruiting
Budapest,H 1122,Hungary
Novartis Investigative Site
Recruiting
Debrecen,4032,Hungary
Novartis Investigative Site
Recruiting
Aviano,PN,33081,Italy
Novartis Investigative Site
Recruiting
Siena,SI,53100,Italy
Novartis Investigative Site
Recruiting
Napoli,80131,Italy
Novartis Investigative Site
Recruiting
Rozzano,MI,20089,Italy
Novartis Investigative Site
Recruiting
Milano,MI,20132,Italy
Novartis Investigative Site
Recruiting
Milano,MI,20133,Italy
Novartis Investigative Site
Recruiting
Milano,MI,20141,Italy
Novartis Investigative Site
Recruiting
Modena,MO,41124,Italy
Novartis Investigative Site
Recruiting
Seoul,03080,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,05505,Korea, Republic of
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08035,Spain
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08036,Spain
Novartis Investigative Site
Recruiting
Madrid,28009,Spain
Novartis Investigative Site
Recruiting
Valencia,Comunidad Valenciana,46010,Spain
Novartis Investigative Site
Recruiting
Hospitalet de LLobregat,Catalunya,08907,Spain
Novartis Investigative Site
Recruiting
Zuerich,8091,Switzerland
Novartis Investigative Site
Recruiting
Taipei,10041,Taiwan
Providence Portland Medical Center
Recruiting
Portland,Ashley Drokin (503-215-6805) email: [email protected] -- Rom Leidner,97123 - Oregon,United States
Columbia University Medical Center- New York Presbyterian
Recruiting
New York,Caitlin Rogers email: [email protected] -- Catherine Shu,10032 - New York,United States
MD Anderson Cancer Center Uni of Te MDACC
Recruiting
Houston,Funda Meric-Bernstam,77030 - Texas,United States
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.